In clinical studies of SLE patients, IFN-γ produced by CD8+ T cells is a key factor in enhancing indoleamine 2,3-dioxygenase (IDO) activity, which promotes the therapeutic effect of allogeneic MSCs in lupus (215). Here, IDO2 is linked to systemic lupus erythematosus.